Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WATERFALL: Zuranolone in Major Depressive Disorder
NCT04442490Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Zuranolone 50 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in the 17-item Hamilton Rating Scale for Depression Total Score at Day 15. Started May 2020; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04442490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442490.